ImmunityBio Inc. (IBRX)
NASDAQ: IBRX · Biological Products, (No Diagnostic Substances) · San Diego, CA
Our rating: Cautious
Cautious reaffirmed at $6.75, moderate conviction, November 10, 2026.
Breaks if: The Cautious view is wrong if ImmunityBio reports an annualized revenue run rate above $350M within four quarters from now while simultaneously narrowing its quarterly net cash burn below $60M — both thresholds must clear together, since either alone would not demonstrate that the cost base is genuinely absorbing the revenue ramp. If that combination appears in the filings, the path to eventual self-funding becomes visible enough to revisit the rating upward.
Key figures
| Market value | $6.4B |
|---|---|
| Revenue, last 12 months | $183M |
| Net income, last 12 months | −$1.1B |
| Free cash flow, last 12 months | −$297M |
| Price to earnings | n/a |
| Free cash flow yield | −4.6% |
| Dividend yield | 0.0% |
| Operating margin | −150.2% |
| Return on equity | n/a |
| Beta to the S&P 500 | 1.52 |
| Volatility, annualized | 97.7% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $49M | 52.3% | $-0.18 | −$78M |
| June 30, 2026 | $51M | 93.9% | $-0.22 | −$70M |
| March 31, 2026 | $44M | 167.6% | $-0.62 | −$77M |
| December 31, 2025 | $38M | 407.0% | $-0.06 | −$71M |
| September 30, 2025 | $32M | 425.1% | $-0.07 | −$70M |
| June 30, 2025 | $26M | 2423.9% | $-0.10 | −$81M |
| March 31, 2025 | $17M | 41192.5% | $-0.15 | −$87M |
| December 31, 2024 | $8M | 5333.1% | $-0.09 | −$87M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.11B: Claude 8%, Gemini 15%, Mistral 25%
- Diluted earnings per share are above zero: Claude 5%, Gemini 3%, Mistral 5%
- Free cash flow for the quarter is above zero: Claude 4%, Gemini 3%, Mistral 5%
38 ledger entries and 51 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.